Evidence map›Paper›PMID 39817390›Full record

ArticleCurrent cancer drug targets2026

Fe

Xue Wang, Tianzhao Xu, Hui Song, Lanmei Zhou, Xinyi Li, Guangli Li, Xinghui Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xue WangDepartment of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Tianzhao XuAffiliated to Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, China.
Hui SongDepartment of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Lanmei ZhouSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Xinyi LiSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Guangli LiPostgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, 200135, China.
Xinghui LiuDepartment of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.

Funding

Clinical Research Project of Health Industry of Shanghai Municipal Health Commission 202140407Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai PWZxq2022-08Shanghai Pudong New Area Health Commission joint research project PW2023D-01Shanghai Pudong New Area Health Commission youth science and technology project PW2021B-01Shanghai Pudong New Area Science and Technology Development Fund public institution livelihood research project PKJ2022-26
6 · The paper itself

Abstract

backgroundLenvatinib is an oral tyrosine kinase inhibitor that selectively inhibits receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous administration of Lenvatinib.

aimsThis study aimed to construct nanocomposites that can efficiently support Lenvatinib and target liver cancer tissues and cells.

objectiveIn this study, ferric oxide-viral-like mesoporous silica nanoparticles-folic acid (Fe

methodsThe hydrothermal method was used to synthesize ferric oxide (Fe

resultsThe experimental data showed that Fe

conclusionLen@ Fe

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsNanoparticlesPhenylurea CompoundsQuinolinesSilicon DioxideAnimalsApoptosisDelayed-Action PreparationsFerric CompoundsHep G2 CellsHumansMiceMice, NudeNanocompositesAntineoplastic AgentsDelayed-Action PreparationsFerric Compoundsferric oxidelenvatinibPhenylurea CompoundsQuinolinesSilicon DioxideFe3O4-vMSNHepatocellular carcinomairon oxide nanoparticlesLenvatinibnanoparticletargeted therapy

Identifiers

PMID39817390

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.